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A SPION-eicosane protective 
coating for water soluble capsules: 
Evidence for on-demand drug 
release triggered by magnetic 
hyperthermia
Laili Che Rose1,6, Joseph C. Bear2, Paul D. McNaughter1, Paul Southern3, R. Ben Piggott4, 
Ivan P. Parkin2, Sheng Qi5 & Andrew G. Mayes1
An orally-administered system for targeted, on-demand drug delivery to the gastrointestinal (GI) tract 
is highly desirable due to the high instances of diseases of that organ system and harsh mechanical and 
physical conditions any such system has to endure. To that end, we present an iron oxide nanoparticle/
wax composite capsule coating using magnetic hyperthermia as a release trigger. The coating is 
synthesised using a simple dip-coating process from pharmaceutically approved materials using a 
gelatin drug capsule as a template. We show that the coating is impervious to chemical conditions 
within the GI tract and is completely melted within two minutes when exposed to an RF magnetic field 
under biologically-relevant conditions. The overall simplicity of action, durability and non-toxic and 
inexpensive nature of our system demonstrated herein are key for successful drug delivery systems.
The ability to deliver drugs to specific sites of action at appropriate doses has long been a goal of medicinal and 
pharmaceutical scientists, due to the potential to avoid whole body side-effects, such as those associated with 
chemotherapeutics. Delivery to the large intestine and bowel is particularly challenging, due to the variety of 
aggressive environments any oral delivery system must survive before arriving at the site of action. The high and 
increasing incidence of bowel disease and the difficulty of delivering sufficiently high drug doses selectively to this 
organ make the gatrointestinal (GI) tract a crucial area for therapeutic systems development1–5. The key advan-
tage of targeted delivery is that higher drug doses can be administered, thus increasing the chance of successful 
therapy whilst reducing side-effects.
Therapeutic applications for nanoparticles have grown exponentially over the last two decades, due in no 
small part to the developments in synthetic and analytical techniques for the preparation of nanoparticles6,7. 
Treatments such as magnetic fluid hyperthermia and photodynamic therapy have seen tremendous success in 
clinical trials for the treatment of tumours, with nanoparticulate systems at the forefront of that success8,9.
Selective targeting of such drug delivery systems has focused largely on the conjugation of cancer targeting 
tags (proteins, peptides, sugars) to nanoparticle surfaces and surface coatings or as part of micellar systems10–12. 
These have proved of limited value due to size restrictions placed on such constructions by the reticuloendothe-
lial system, which clears foreign bodies above 20 nm in [hydrodynamic] diameter13. Many systems focus on the 
treatment of tumours via the vascular network, but as yet, “on-demand” drug delivery systems for exclusive use in 
the GI tract are under-developed. Current systems rely on simple pH switches or degradation through bacterial 
enzyme action, which can be somewhat unpredictable and offers limited control. To address this problem, we 
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propose a drug delivery system for use in the GI tract, with potential for magnetic targeting and tracking, which 
can release its payload on demand using localised magnetic hyperthermia to trigger release. The system we pro-
pose is shown in Fig. 1.
Briefly, standard gelatin capsules were dip coated into a dispersion (10 wt%) of oleic acid-capped superpara-
magnetic iron oxide nanoparticles (SPIONs) in molten eicosane at 50 °C. This renders the capsule impervious to 
water/acid/base ingress and thus provides a coating that is resistant to the harsh conditions experienced in the 
GI tract. This was demonstrated by dissolution testing of dip-coated paracetamol-filled capsules in pH 1.2 HCl 
and FASSIF (fasted state simulated intestinal fluid - buffer and bile salts mimicking the intestine) at 37 °C. No 
drug release was observed for periods up to 24 hours under these conditions. At the desired delivery point, brief 
irradiation (a few minutes) from a radio frequency (RF) field with a frequency and field strength acceptable for 
therapeutic use14 causes localised magnetically-induced heating of the wax coating to a temperature just above its 
melting point but insufficient to cause tissue damage. The exact melting point can be tuned by mixing eicosane 
and docosane in various ratios to raise the melting point to just above body temperature. Melting the wax triggers 
fluid ingress and capsule rupture, delivering the contents into solution. Post-delivery, the ruptured capsule rem-
nants and nanoparticles would then be excreted harmlessly in the patient’s stool.
When developing a delivery system, it is essential to consider bio-compatibility and toxicity and it is pref-
erable only to use pharmaceutically-approved materials. This rationale informed selection of the nanoparticle 
synthesis method and SPION loadings, which are lower than guidelines for iron oxide contrast agents (table S1), 
but sufficient to cause the required response. Many other synthetic approaches provide superior control of size 
and polydispersity15,16, but the aqueous precipitation method chosen used only approved compounds and can 
be scaled easily to produce large amounts of iron oxide nanocrystals, whose size range could be controlled by 
varying the amount of oleic acid included in the synthesis. Analysis of the products by TEM and DLS confirmed 
that nanocrystals of about 10–20 nm could be synthesised reproducibly (Fig. 2a,b). Powder XRD produced pat-
terns consistent with iron oxide (most likely magnetite Fe3O4) (Fig. 2c). SQUID measurements gave a saturation 
magnetization value of 59 emu g−1 and zero coercivity at 300 K, typical of iron oxide nanocrystals in this size 
regime (Fig. 2d)17. ATR-FTIR measurements of the purified oleic acid coated nanocrystals were difficult due to 
the broad-band IR absorbance of iron oxide, but the spectra were sufficient to confirm the presence of the oleic 
acid capping layer (Fig. S7) .
Figure 1. The process of capsule exposure and drug release. (a) An iron oxide and eicosane coated capsule, 
(b) upon exposure to radiowaves, heating occurs causing melting and formation of holes in the coating and 
exposure of the capsule to the surrounding environment, (c) fluid ingress causes capsule dissolution and (d) 
drug release.
Figure 2. (a) TEM micrograph of ~10 nm iron oxide nanoparticles, (b) an average DLS size (by number, 
10.1 nm) of the aforementioned nanoparticles, (c) an XRD pattern of iron oxide nanoparticles and (d) a SQUID 
magnetometry measurement showing a saturation magnetisation of 59 emu g−1.
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Images of a coated capsule and a section showing the coating thickness are shown in Figs S3–S5. The 
dip-coating method used in this work, although crude, produced reproducible coating thicknesses with no 
defects that compromised surface protection. For these experiments, three dipping cycles were used to give an 
overall coating thickness of 1.5 ± 0.39 mm, and were shown to be impervious to pH and FASSIF buffer ingress 
using gut mimicking conditions and timescales at 37 °C (body temperature) (Fig. S6).
Heating experiments were first conducted in air by placing the dry capsule in a polystyrene weighing boat bal-
anced on the top surface of the RF coil (Resonant circuits Limited)18 and monitoring using the thermal imaging 
camera while the capsule was irradiated at a frequency and field strength of 1 MHz and 7.5 mT respectively. Visual 
observation clearly showed the melting of the wax due to magnetically-induced heating in air (Fig. 3e,f). The tem-
perature maps obtained from thermal imaging (Fig. 3a–d) show the beginning of the melting process along one 
edge of the capsule and an end point where the hot wax has run off the capsule surface, reaching a temperature of 
~60 °C after 3 minutes irradiation. Videos showing the evolution of heat maps with time are available to view in 
the SI. Similar results were recorded for capsules half-submerged at the surface of 10 mL of FASSIF buffer, with 
dye-release observed on irradiation once the coating had melted (Fig. S2).
Temperature versus time data was extracted from the thermal image data and representative heating curves 
are plotted in Fig. 4. The curves displayed initial heating to a plateau value consistent with the melting point of 
eicosane (35–37 °C - confirmed by DSC measurements – see Fig. S1). At this point energy is required to supply 
the latent heat of melting, hence a plateau is observed as the material undergoes phase transition to the liquid. 
Once liquefied, rapid heating is observed, which tails off at high temperatures due to thermal diffusion to the 
external environment. Interestingly, the initial gradient of the heating curve, when the wax is still solid, is shal-
lower than the gradient observed after melting. We interpret this as showing the difference in heating mechanisms 
available for nanoparticles in a constrained solid matrix (Néel heating only) compared with freely rotating parti-
cles in a dispersion (Néel and Brownian heating).
Figure 3. Thermal images of the coated capsules in the presence of the alternating magnetic field at time 
t = (a) 30 s, (temperature maximum 35.43 °C) (b) 90 s, (temperature maximum 37.33 °C) (c) 150 s, (temperature 
maximum 51.12 °C) and (d) 210 s, (temperature maximum 64.54 °C). The drawn circle surrounding the capsule 
indicates the position of the RF coil. Photographs of the coated capsule above the RF coil (e) before and (f) after 
exposure to the alternating magnetic field.
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The synthesis, characterisation and activation mechanism of a magnetic hyperthermia triggered drug delivery 
system for on-demand drug delivery has successfully been demonstrated, and the release mechanism evaluated 
in aqueous systems mimicking the intestine. Integrating this system with targeting and locating devices such as 
magnetic field gradients and MRI is the subject of ongoing research. This is one of the only instances of the use of 
nanoparticles for on-demand drug release in a non-intravascular drug delivery system and has huge potential for 
treatment of GI diseases ranging from Crohn’s disease and ulcerative colitis to cancers.
Materials
Iron(II) sulphate heptahydrate (≥ 99%), iron(III) chloride hexahydrate (97%) were purchased from Alfa Aesar. 
Sodium hydroxide pellets (Analytical reagent grade) and ammonium hydroxide solution (28% in water) were 
purchased from Fisher Scientific Limited. Oleic acid (technical grade, 90%) and eicosane (99%) were purchased 
from Sigma Aldrich Limited and used as received. Laboratory solvents were purchased from Sigma Aldrich 
Limited and were of the highest possible grade. Aqueous solutions were prepared using UHQ deionised water 
with a resistivity of not less than 18.2 MΩ cm−1.
Methods
Iron oxide (Fe3O4) nanoparticles were synthesised using the chemical co-precipitation reaction between iron(II) 
and iron(III) salts in basic media in the presence of oleic acid using a slight modification of the approach 
described by López-López et al.19. Briefly, iron(III) chloride hexahydrate (34.0 g, 125.8 mmol) was dissolved in 
deionised water (175 mL) and mixed with a solution of iron(II) sulphate heptahydrate (18.0 g, 64.7 mmol) in 
deionised water (200 mL) in a molar ratio of 1:2 in a nitrogen purged reactor. Ammonium hydroxide solution was 
added under vigorous stirring in order to achieve a pH of 10, before addition of oleic acid (10 mL, 31.5 mmol). 
Figure 4. (a) Heating curve of 10 wt.% nanoparticles in eicosane in air and (b) immersed in FASSIF buffer, 
mimicking conditions in the gut. The capsule (solid line) shows similar heating characteristics to (a). The 
temperature of the surrounding FASSIF buffer (dashed line) also increased due to heat transfer from the melted 
capsule coating and the induction coil.
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The dark brown suspension was subsequently heated to 95 °C, before cooling naturally to room temperature as 
soon as 95 °C was reached. The nanoparticles were precipitated by addition of 1 mol dm−3 HCl solution. The liq-
uid was decanted, before isolation of the nanoparticles by centrifugation (1000 × g) and washing with 3 × 100 mL 
portions of deionised water and ethanol respectively. Finally, the precipitate was dried in a vacuum desiccator.
The nanoparticle-eicosane layer was applied to the capsules by dip-coating a gelatin capsule on the end of a 
smoothed glass suction tube (connected to a membrane-type vacuum pump) into an homogenised (Ultra Turrax 
T4, IKA, Germany) molten suspension of 10 wt.% iron oxide nanoparticles in molten eicosane (ca. 50 °C). A com-
plete coating was achieved by waiting for the molten layer to cool before reversing the capsule to coat the second 
end with a small overlap in the centre to ensure complete coverage. The process was repeated for the addition of 
subsequent layers up to a total of 3 layers (1.5 mm thickness). A custom glass tube with multiple arms was con-
structed for dipping several capsules simultaneously.
Hyperthermia experiments were undertaken using a MACH (Magnetic Alternating Current Hyperthermia) 
system designed and built by Resonant Circuits Limited18. The 3-turn coil was 44 mm in diameter, water cooled 
and generated a maximum field strength of 9.2 mT at 1 MHz frequency. The temperature was monitored using a 
fluoroptic temperature probe (Luxtron FOT Lab Kit, Lumasense California USA). Thermal images were recorded 
with an Infratec (Germany) VarioCAM HR research 780 with 30 mK thermal resolution and 1280 × 960 spatial 
resolution. Other instrumentation details can be found in section S3.
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